* **Celiac Disease Full Text Screening Tool**

1. Should the study have been rejected at abstract screening? If yes, please state the reason.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  Yes (STOP), submit formSpecify:

|  |
| --- |
|  Not English language |
|  Not human |
|  Not about celiac disease (CD) |
|  Not about diagnosis of CD or under-diagnosis of CD |
|  No original data - letter, commentary, editorial, etc. |
|  Individual case report |
|  Prevalence, outside U.S. |
|  Diagnostic method outside the scope of study. (Diagnostic methods included in the KQs are Endomysial antibodies (EmA) test,Anti-tissue Transglutaminase (tTG) test, Deamidated Gliadin Peptide (DGP) antibody, HLA typing, video capsule endoscopy, and endoscopy with biopsy) |
|  Test processing issue (E.g., PCR vs. other method) |
|  Serology Only |
|  Pre dates systematic review (SR) on topic |
|  |

 |
|  No |
|  |

2. Does the article address Key Question 4 - adverse effects of invasive methods (endoscopy with biopsy, video capsule endoscopy)?

|  |
| --- |
|  Yes (STOP), submit form - study will be included |
|  No |
|  |

3. Does the article address Key Question 2 - how the accuracy of duodenal biopsy varies by MD training, method, or length of gluten ingestion?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  Yes (STOP), submit form - study will be includedIf yes, indicate which one:

|  |
| --- |
|  Pathologist characteristics, i.e. level of experience or specific training |
|  Method, i.e. type or number of specimens |
|  Length of time ingesting gluten before diagnostic testing |
|  Exclude study (indicate reason) |  |

 |
|  No |
|  |

4. Does the article address Key Question 1 or Key Question 3 - assess the accuracy or effectiveness (e.g. outcomes) of any of the following? (check all that apply)

|  |
| --- |
|  Endomysial antibodies (EmA) IgA test |

|  |
| --- |
|  Anti-tissue transglutaminase (tTG) IgA test |
|  EmA IgG, tTG IgG, and DGP IgG tests for IgA deficient individuals |
|  Deamidated Gliadin Peptide (DGP) IgA Antibodies |
|  HLA-DQ2 or HLA-DQ8 |
|  Video capsule endoscopy |
|  None of the above (STOP), submit form - study will be excluded |
|  Does not assess accuracy or effectiveness e.g. only prevalence, test processing, etc. (STOP), submit form - study will be excluded |

5. If this is an accuracy study:

Are the tests compared to biopsy?

|  |
| --- |
|  Yes |
|  No (STOP), submit form - study will be excluded |
|  |

Did ALL subjects undergo both the "intervention" diagnostic method and the "reference" standard (usually biospy)?

(i.e. everyone who received a serological test should get biopsy too, regardless of whether the test was negative or positive)

|  |
| --- |
|  Yes |
|  No (STOP), submit form - study will be excluded |
|  |

6. What is the sample size?



7. Was a consecutive or random sample of patients enrolled?

|  |
| --- |
|  Yes |
|  No |
|  Unclear |
|  |

8. Does the article present results specific to the following populations? (check all that apply)

|  |
| --- |
|  Children, under age 24 months vs. older children & adolescents |
|  Adults (aged 18+) |
|  Ethnic or geographic populations (Specify) |  |
|  Low socioeconomic status (SES) |  |
|  IgA deficient |  |
|  Previously negative for CD |  |
|  With signs and symptoms of CD (i.e., diarrhea, nutrional deficits, etc.) |  |

|  |  |
| --- | --- |
|  With type 1 diabetes |  |
|  With auto-immune disease |  |
|  With Turner's syndrome |  |
|  With trisomy 21/Down Syndrome |  |
|  With family history |  |
|  Other special population (Specify) |  |
|  General population, no special populations |  |

9. Does the article need further discussion?

|  |
| --- |
|  Yes |
|  No |

Notes:

